3 recruiting, 3 terminated, 3 withdrawn, 2 completed. 10 Phase 2, 8 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Recruiting 3, Completed 2, Terminated 2, Withdrawn 2, Active not recruiting 1 |
| Phase 1 | 8 | Withdrawn 3, Completed 2, Recruiting 2, Active not recruiting 1 |
| Phase 3 | 1 | Terminated 1 |
Follow Faron Pharmaceuticals Ltd: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Bexmarilimab + Azacitidine Versus Placebo + Azacitidine in Participants With Treatment-naïve Higher-risk Myelodysplastic Syndromes bexmarilimab (1mg/kg), azacitidine, Placebo - Higher Risk Myelodysplastic Syndromes | Phase 2 | Recruiting | Faron Pharmaceuticals Ltd | 90 | 2026-10-01 | 2026-10-20 |
| Investigating the Combination of Bexmarilimab and Nivolumab in Solid Tumours, Melanoma and NSCLC Bexmarilimab 1mg/kg and nivolumab 1mg/kg, Bexmarilimab 3mg/kg and nivolumab 1mg/kg, Recommended Phase II Dose - Melanoma (Skin Cancer), Non Small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Institute of Cancer Research, United Kingdom | 62 | 2026-08-28 | 2026-09-08 |
| A Phase Ib/II Study to Evaluate Safety and Efficacy of Bexmarilimab in Combination With Doxorubicin in Metastatic Soft-tissue Sarcoma. bexmarilimab, Doxorubicin - Soft Tissue Sarcoma (STS) | Phase 1 / Phase 2 | Recruiting | MedSIR | 278 | 2026-08-20 | 2026-08-31 |
| Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy Interferon Beta-1A, X-Ray Imaging, Echocardiography - Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Withdrawn | Fred Hutchinson Cancer Center | 2025-04-01 | 2024-07-12 | |
| Dose Escalation Trial of Bexmarilimab (FP-1305) Plus Pembrolizumab in Non-Small Cell Lung Cancer bexmarilimab (FP-1305), Pembrolizumab - Non-small Cell Lung Cancer | Phase 1 | Withdrawn | The University of Texas Health Science Center at San Antonio | 2023-06-01 | 2023-07-20 | |
| A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies Bexmarilimab, Azacitidine, Venetoclax - Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia | Phase 1 / Phase 2 | Active not recruiting | Faron Pharmaceuticals Ltd | 181 | 2022-06-02 | 2026-04-23 |
| A Phase I/II Open Label Single Centre Trial to Assess the Safety, Tolerability and Efficacy of Single Dose Neoadjuvant Anti-CLEVER-1 Antibody Bexmarilimab in Localised Renal Cell and Colon Carcinoma bexmarilimab - Carcinoma, Renal Cell, Carcinoma Colon | Phase 1 / Phase 2 | Withdrawn | Faron Pharmaceuticals Ltd | 2021-10-07 | 2022-05-11 | |
| Human Intravenous Interferon Beta-Ia Safety and Preliminary Efficacy in Hospitalized Subjects With COVID-19 IFN beta-1a, Dexamethasone - Covid19 | Phase 2 | Terminated | Faron Pharmaceuticals Ltd | 7 | 2021-08-23 | 2023-07-21 |
| A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS) FP-1305 (bexmarilimab) - Cancer | Phase 1 / Phase 2 | Completed | Faron Pharmaceuticals Ltd | 216 | 2018-12-03 | 2025-04-02 |
| Efficacy and Safety of FP-1201-lyo (Interferon Beta-1a) in Prevention of Multi-Organ Failure on Patients After Open Surgery for a RAAA Interferon Beta-1A, Placebo - Preventive Medicine, Multi Organ Failure | Phase 2 | Terminated | Faron Pharmaceuticals Ltd | 40 | 2017-02-18 | 2021-01-14 |
| Efficacy and Safety of FP-1201-lyo (Interferon Beta-1a) in Patients Having Acute Respiratory Distress Syndrome (ARDS) Interferon beta-1a, Placebo - Respiratory Distress Syndrome, Adult | Phase 3 | Terminated | Faron Pharmaceuticals Ltd | 301 | 2015-12-23 | 2020-03-30 |
| Safety, Tolerability and Preliminary Efficacy of FP-1201 in ALI and ARDS. Phase I/II Interferon Beta - Acute Lung Injury, Acute Respiratory Distress Syndrome | Phase 1 / Phase 2 | Completed | Faron Pharmaceuticals Ltd | 37 | 2009-02-01 | 2015-05-27 |
Carcinoma, Non-Small-Cell Lung (2) · Neoplasms (2) · Respiratory Distress Syndrome (2) · Acute Lung Injury (1) · Burkitt Lymphoma (1) · COVID-19 (1) · Carcinoma, Renal Cell (1) · Colonic Neoplasms (1) · Hematologic Neoplasms (1) · Leukemia, Myeloid, Acute (1) · Leukemia, Myelomonocytic, Chronic (1) · Lymphoma, B-Cell (1) · Lymphoma, Mantle-Cell (1) · Melanoma (1) · Multiple Organ Failure (1)
bexmarilimab (7) · Interferon beta-1a (3) · Azacitidine (2) · Biopsy (1) · Dexamethasone (1) · Doxorubicin (1) · Drugs, Investigational (1) · Interferon-beta (1) · Magnetic Resonance Spectroscopy (1) · Nivolumab (1) · Phantoms, Imaging (1) · Spinal Puncture (1) · X-Rays (1) · peginterferon beta-1a (1) · pembrolizumab (1)
Finland (6) · United Kingdom (6) · United States (6) · France (3) · Spain (3) · Czechia (2) · Italy (2) · Belgium (1) · Estonia (1) · Germany (1) · Lithuania (1) · Netherlands (1) · Poland (1)
Adit Ginde, MD MPH, (1) · Alan Davidson, MD (1) · Alexander Binning, MD (1) · Daniel Talmor, MD MPH, (1) · Dr Anna Minchom, MB BCh, FRCP, MD (Res) (1) · Geoff Bellingan, MD (1) · Geoffrey Bellingan, MD (1) · Harri Hakovirta, MD (1) · Jordan Gauthier (1) · Maarit Venermo, MD (1) · Martin Kuper, MD (1) · Martin Stotz, MD (1) · Mathew Wise, MD (1) · Mika Kontro, MD, PhD (1)
PMID 24503265, PMID 32065831, PMID 34078651, PMID 35115574, PMID 35500016, PMID 36927455, PMID 38056464, PMID 40369178, PMID 40449509
2014 (2), 2018 (1), 2025 (1)